Onconetix Inc
Research Onconetix Inc (ONCO) on Bullrun: market cap USD 2.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerONCO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.24M
- Financial periodQ2 2026
- RevenueUSD 17.12K
- Net income-USD 2.87M
- Free cash flow-USD 1.92M
- Gross margin25.1%
Valuation Snapshot
latest market cap is USD 2.24M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 815.37K | -USD 14.03M | -USD 9.68M | 77.6% | -16.56 | USD 5.22M | USD 48.77K | USD 15.76M |
| FY2024 | USD 2.52M | -USD 58.69M | -USD 10.52M | 41.8% | -1823.39 | USD 646.50K | USD 9.45M | USD 8.54M |
| FY2023 | USD 58.47K | -USD 37.41M | -USD 13.58M | -1927.9% | -87.45 | USD 4.55M | USD 9.89M | -USD 5.60M |
| FY2022 | USD 0 | -USD 13.42M | -USD 8.68M | n/a | -1.1 | USD 25.75M | USD 0 | USD 22.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 2.24M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 7.42M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.38M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.83M | n/a | n/a | n/a |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2022 | 1.23 USD |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Onconetix Inc's market cap?
Onconetix Inc's market capitalization is USD 2.24M.
What does Onconetix Inc do?
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc.